Entrada Therapeutics financials
$6.26+0.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $898.0K | $875.0K | $1.3M | $1.6M | $1.9M | $20.6M | $37.4M | $19.6M | $94.7M | $59.1M | $41.8M | $43.7M |
| Gross profit | $898.0K | $875.0K | $1.3M | $1.6M | $1.9M | $20.6M | $37.4M | $19.6M | $94.7M | $59.1M | $41.8M | $43.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$45.0M | -$42.3M | -$42.2M | -$47.1M | -$46.8M | -$21.8M | -$5.9M | -$21.7M | $53.4M | $21.1M | $4.9M | $14.0M |
| Net income | -$42.8M | -$39.7M | -$39.2M | -$44.1M | -$43.1M | -$17.3M | $1.1M | -$14.0M | $55.0M | $23.5M | -$9.5M | $35.5M |
| Net margin | −4762.0% | −4539.1% | −3014.9% | −2734.4% | −2210.4% | −84.4% | 3.0% | −71.7% | 58.1% | 39.7% | −22.8% | 81.1% |
| Diluted EPS | $-1.01 | $-0.95 | $-0.94 | $-1.06 | $-1.04 | $-0.42 | $0.03 | $-0.35 | $1.55 | $0.68 | $-0.30 | $1.02 |
| EBITDA | -$44.1M | -$41.5M | -$41.3M | -$45.8M | -$45.8M | -$20.8M | -$4.9M | -$20.7M | $54.3M | $22.0M | $5.6M | $14.8M |
| Operating cash flow | -$32.5M | -$41.7M | -$32.2M | -$28.3M | -$29.5M | -$38.5M | -$31.6M | -$24.3M | $39.8M | -$25.5M | -$4.0M | -$24.5M |
| Free cash flow | -$32.5M | -$41.7M | -$32.4M | -$28.5M | -$29.8M | -$39.7M | -$32.2M | -$24.9M | $38.8M | -$26.4M | -$5.0M | -$25.9M |
| Diluted shares | 42.2M | 41.8M | 41.6M | 41.5M | 41.3M | 41.1M | 45.1M | 40.6M | 35.5M | 34.8M | 31.9M | 34.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $99.3M | $76.4M | $90.4M | $93.3M | $72.5M | $67.8M |
| Short-term investments | $123.7M | $178.4M | $205.3M | $233.6M | $281.5M | $314.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $298.9M | $335.5M | $377.4M | $412.9M | $448.8M | $486.5M |
| Total liabilities | $65.5M | $64.7M | $71.2M | $72.2M | $69.3M | $69.2M |
| Shareholders' equity | $233.4M | $270.9M | $306.1M | $340.7M | $379.5M | $417.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology